This Contract IS to Advance the Development of Monovalent Vaccines for Prevention of Marburg Virus (marv) and Sudan Ebolavirus (sudv) Disease
Contract Overview
Contract Amount: $147,062,009 ($147.1M)
Contractor: Albert B. Sabin Vaccine Institute, Inc. (THE)
Awarding Agency: Department of Health and Human Services
Start Date: 2019-09-26
End Date: 2026-09-30
Contract Duration: 2,561 days
Daily Burn Rate: $57.4K/day
Official Description: THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.
Place of Performance
Location: District of Columbia, 20515